Sanofi (XPAR:SAN) Capex-to-Revenue

: 0.00 (As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sanofi's Capital Expenditure for the six months ended in Jun. 2023 was €0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was €21,545.00 Mil.

Hence, Sanofi's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.00.

Sanofi Capex-to-Revenue Historical Data

The historical data trend for Sanofi's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

0.05

0.06

0.05

0.07

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue																-	0.05	0.05	-	-

Competitive Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi Capex-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sanofi's Capex-to-Revenue falls into.

Sanofi Capex-to-Revenue Calculation

Sanofi's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-3024)	/	46444
	=	0.07

Sanofi's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	21545
	=	0.00

Sanofi (XPAR:SAN) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Sanofi Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sanofi's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (XPAR:SAN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (XPAR:SAN) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.